Plant
UnitedHealth Group Names Mike Cotton as New Medicaid CEO in Executive Reshuffle
UnitedHealth Group; CEO appointment; Medicaid; Mike Cotton; executive changes; government programs; Bobby Hunter; leadership transition
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Vanda Escalates Vendetta Against FDA, Blasts Bureaucrats for Delaying Stomach Drug
United States Food and Drug Administration, Vanda, United States Food and Drug Administration, Gastroparesis, Translucent
Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial
Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Lila Sciences Emerges with $200M to Build AI-Powered Scientific Superintelligence Platform
AI, scientific discovery, autonomous labs, Flagship Pioneering, seed funding
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup
Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma
Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders
Appeals Court Upholds FDA’s Denial of Fast Track Designation for Vanda’s Gastroparesis Drug
FDA, Vanda Pharmaceuticals, Fast Track Designation, Gastroparesis, Drug Approval Process